Rainer Strohmenger

Managing Partner at Wellington Partners

Speaker

Dr Rainer Strohmenger joined Wellington Partners in 1997 and became a Partner in 2000 with responsibility for the Life Science portfolio. During his 27 years in venture capital, he has been responsible for the financing of more than 30 portfolio companies, 7 of which were taken public (including Actelion, Oxford Immunotec and immatics), and 9 were successfully exited through trade sales (incl. MTM Laboratories acquired by Roche, Definiens acquired by AstraZeneca, invendo medical acquired by Ambu).

Dr Strohmenger represents Wellington on the boards of its portfolio companies Adrenomed (Berlin), AMB (Waghäusel/Heidelberg), Aignostics (Berlin), Amboss (Berlin), eGenesis (Boston/board observer), iOmx (Munich), Koa Health (Amsterdam/Barcelona), Quanta (Birmingham) and SphingoTec (Berlin).

Prior to joining Wellington, Dr Strohmenger was involved in research work in the fields of cardiovascular physiology and health economics. He holds a Doctor of Medicine and a Master of Economics degree, both from Ludwig-Maximilians-University, Munich (Germany), and was trained at the Entrepreneurship Center of MIT, Boston (USA).

Dr Strohmenger is a Honorary Senator of the German Association of Small and Medium-sized Businesses (BVMW) and served as a Member of the Venture Capital Council at InvestEurope.